Q-omics provides the consensus-scored COBLL1 profile across patient tissues and cancer cell-line models. COBLL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COBLL1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, COBLL1 protein abundance shows 20,212 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where COBLL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COBLL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COBLL1 survival associations across molecular data types. COBLL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COBLL1 RNA expression–survival associations across cancer types. High COBLL1 expression shows unfavorable associations in UCEC and LGG, but favorable associations in KIRC, UVM, KIRP and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COBLL1 RNA expression.
This table summarizes COBLL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COBLL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COBLL1 shows lower tumor expression in KIRC, LUAD, KICH, KIRP, BRCA and ESCA. The KIRC box plot shows higher COBLL1 RNA expression in normal versus tumor tissue (log2 FC = −2.385, t-test p < 0.001).
This table shows molecular features associated with COBLL1 in patient tissues and cancer cell lines. In patient samples, COBLL1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, COBLL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
